SCHEMBL3155189

SCHEMBL3155189

O=S(=O)(O)c1cnc2ccccn12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.44
NPC1 O15118 7/20 0.44
RAB9A P51151 6/20 0.44
NPSR1 Q6W5P4 2/20 0.44
GGPS1 O95749 1/20 0.43
FDPS P14324 1/20 0.43
MIF P14174 1/20 0.43
FLT3 P36888 1/20 0.42
EPHB3 P54753 1/20 0.41
ALDH1A1 P00352 7/20 0.40
HTT P42858 1/20 0.40
DRD2 P14416 2/20 0.39
HTR2A P28223 2/20 0.39
HTR7 P34969 2/20 0.39
HTR6 P50406 2/20 0.39
SMN1; SMN2 Q16637 5/20 0.39
HPGD P15428 4/20 0.39
MAPT P10636 2/20 0.39
TP53 P04637 2/20 0.39
CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9525882 0.82 TGFBR1 (0.46) ADORA3NPC1RAB9ANPSR1GGPS1
SCHEMBL792707 0.82 ADORA3 (0.44) ADORA3NPC1RAB9ANPSR1GGPS1
SCHEMBL24803763 0.79 ADORA3 (0.42) ADORA3NPC1RAB9ANPSR1GGPS1
SCHEMBL9075915 0.77 EPHB3 (0.41) ADORA3NPC1RAB9ANPSR1GGPS1
SCHEMBL21808337 0.73 HTR2A (0.42) ADORA3NPC1RAB9ANPSR1GGPS1
SCHEMBL18766632 0.72 MAP3K14 (0.41) FLT3HTR6POLBTSHRKDM4E
SCHEMBL17102638 0.72 NPC1 (0.41) ADORA3NPC1RAB9ANPSR1GGPS1
SCHEMBL4557281 0.71 AKR1B1 (0.52)
SCHEMBL3313454 0.71 MIF (0.53) ADORA3NPC1RAB9ANPSR1GGPS1
SCHEMBL4557262 0.70 PIK3CA (0.39) ADORA3NPC1RAB9ANPSR1FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115569-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS LARIO THERAPEUTICS LTD (GB) 2025-04-10 US disclosed
EP-4436955-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS Lario Therapeutics Limited (GB) 2024-10-02 EP disclosed
CN-118317950-A Sulfonamide compounds for the treatment of neurological disorders 拉里奥治疗有限公司 2024-07-09 CN disclosed
WO-2023094830-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS LARIO THERAPEUTICS LIMITED (GB) 2023-06-01 WO disclosed
WO-2023094830-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS LARIO THERAPEUTICS LIMITED (GB) 2023-06-01 WO disclosed
CN-112538087-B Synthesis method of imidazopyridine compound 温州大学新材料与产业技术研究院 2021-10-15 CN disclosed
CN-112538087-A Synthesis method of imidazopyridine compound 温州大学新材料与产业技术研究院 2021-03-23 CN disclosed
EP-2233493-A1 Macrolides Pfizer Products Inc. (US) 2010-09-29 EP disclosed
EP-1836211-B1 MACROLIDES PFIZER PROD INC (US) 2010-03-03 EP disclosed
US-7462600-B2 Macrolides PFIZER INC (US) 2008-12-09 US disclosed
EP-1836211-A1 MACROLIDES Pfizer Products Incorporated (US) 2007-09-26 EP disclosed
WO-2006067589-A1 MACROLIDES PFIZER PRODUCTS INC. (US) 2006-06-29 WO disclosed
US-20060135447-A1 Macrolides CHUPAK LOUIS S 2006-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135447-A1 Macrolides LCAT, NOP2, HDAC6 ADORA3 2516/4885NPC1 16/4885RAB9A 2242/4885
US-20250115569-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS CACNA1A, CACNA1E, CACNA1S ADORA3 1359/4885NPC1 3262/4885RAB9A 417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.